Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: An apparatus can include a generally planar portion approximately in a plane. The apparatus can also include a lip portion extending in a direction generally orthogonal to the plane. The generally planar portion is joined to the lip portion at a circumferential edge of the generally planar portion to form a cover for a beverage container. Likewise, a method can include providing contact information on a disposable cover adapted to cover a beverage container. The contact information is not necessarily provided by the manufacturer of the beverage or beverage container. The method can also include receiving contact from a user of the disposable cover. The method can further include coordinating the delivery of a service to the user of the disposable cover responsive to the contact received from the user.

Abstract: Provided are anti-syndecan-2 antibodies and compositions comprising said antibody and methods useful for treating acute respiratory distress syndrome, including coronavirus disease 2019-induced acute respiratory distress syndrome, in a subject in need thereof. The method comprises administering to the subject an effective amount to treat the acute respiratory distress syndrome of an syndecan-2 disrupting agent. The syndecan-2 disrupting agents may include at least one of the anti-syndecan-2 antibodies and/or at least one syndecan-2 disrupting peptide.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: In various aspects and embodiments, the invention provides methods of treating pulmonary arterial hypertension by inhibiting the endothelial to mesenchymal transition. The invention provides a method of treating pulmonary arterial hypertension (PAH) in a subject, the method comprising administering to the subject an agent that modulates the activity or level of let-7 mlRNA in an endothelial cell in the subject, thereby treating PAH in the subject. In another aspect, the invention provide a method of treating PAH in a subject, the method comprising administering to the subject an agent that decreases the activity or level of an endothelial TGF? signaling polypeptide or a TGF? peptide receptor, thereby treating PAH in the subject.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: An apparatus can include a generally planar portion approximately in a plane. The apparatus can also include a lip portion extending in a direction generally orthogonal to the plane. The generally planar portion is joined to the lip portion at a circumferential edge of the generally planar portion to form a cover for a beverage container. Likewise, a method can include providing contact information on a disposable cover adapted to cover a beverage container. The contact information is not necessarily provided by the manufacturer of the beverage or beverage container. The method can also include receiving contact from a user of the disposable cover. The method can further include coordinating the delivery of a service to the user of the disposable cover responsive to the contact received from the user.

Abstract: In various aspects and embodiments the invention provides compositions and methods useful in the treatment of diseases related to vascular permeability. In another aspect, the invention provides a method of treating a vascular permeability related disease in a subject, the method comprising administering to the subject an effective amount of a syndecan-2 disrupting agent.

Abstract: An apparatus can include a generally planar portion approximately in a plane. The apparatus can also include a lip portion extending in a direction generally orthogonal to the plane. The generally planar portion is joined to the lip portion at a circumferential edge of the generally planar portion to form a cover for a beverage container. Likewise, a method can include providing contact information on a disposable cover adapted to cover a beverage container. The contact information is not necessarily provided by the manufacturer of the beverage or beverage container. The method can also include receiving contact from a user of the disposable cover. The method can further include coordinating the delivery of a service to the user of the disposable cover responsive to the contact received from the user.

Abstract: The invention relates to compositions and methods for reducing excessive vascular development and treat related disorders. In one aspect, the invention provides methods for treating, reducing or inhibiting vascular development in a subject in need thereof. The methods of the invention comprises administering to the subject an effective amount of a HK2 depleting agent that decreases the level of expression and/or activity of HK2. In some embodiments, the level of expression and/or activity of fibroblast growth factor receptor (FGFR), FGF ligand and/or FGF signaling is/are decreased. The invention also includes methods for diagnosing excessive vascular development and for measuring the efficacy of a treatment for an excessive vascular development in a subject in need thereof. The invention further includes a pharmaceutical composition for treating or reducing angiogenesis or lymphangiogenesis, comprising a HK2 depleting agent and a pharmaceutical acceptable carrier.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: An apparatus can include a generally planar portion approximately in a plane. The apparatus can also include a lip portion extending in a direction generally orthogonal to the plane. The generally planar portion is joined to the lip portion at a circumferential edge of the generally planar portion to form a cover for a beverage container. Likewise, a method can include providing contact information on a disposable cover adapted to cover a beverage container. The contact information is not necessarily provided by the manufacturer of the beverage or beverage container. The method can also include receiving contact from a user of the disposable cover. The method can further include coordinating the delivery of a service to the user of the disposable cover responsive to the contact received from the user.

Abstract: The invention relates to compositions and methods for reducing excessive vascular development and treat related disorders. In one aspect, the invention provides methods for treating, reducing or inhibiting vascular development in a subject in need thereof. The methods of the invention comprises administering to the subject an effective amount of a HK2 depleting agent that decreases the level of expression and/or activity of HK2. In some embodiments, the level of expression and/or activity of fibroblast growth factor receptor (FGFR), FGF ligand and/or FGF signaling is/are decreased. The invention also includes methods for diagnosing excessive vascular development and for measuring the efficacy of a treatment for an excessive vascular development in a subject in need thereof. The invention further includes a pharmaceutical composition for treating or reducing angiogenesis or lymphangiogenesis, comprising a HK2 depleting agent and a pharmaceutical acceptable carrier.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: An apparatus can include a generally planar portion approximately in a plane. The apparatus can also include a lip portion extending in a direction generally orthogonal to the plane. The generally planar portion is joined to the lip portion at a circumferential edge of the generally planar portion to form a cover for a beverage container. Likewise, a method can include providing contact information on a disposable cover adapted to cover a beverage container. The contact information is not necessarily provided by the manufacturer of the beverage or beverage container. The method can also include receiving contact from a user of the disposable cover. The method can further include coordinating the delivery of a service to the user of the disposable cover responsive to the contact received from the user.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.